Adage Capital Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Adage Capital Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-32,057	Closed	-$7.24M	–	1061
2022 Q3	$7.24M	Sell	32,057 -2,943	-8%	-$723K	0.02%	720
2022 Q2	$6.62M	Sell	35,000 -21,667	-38%	-$4.37M	0.02%	766
2022 Q1	$14.1M	Buy	+56,667	New	+$8.96M	0.03%	598
2020 Q4	–	Sell	-8,333	Closed	-$2.04M	–	893
2020 Q3	$2.04M	Sell	8,333 -8,334	-50%	-$2.59M	0.01%	700
2020 Q2	$4.8M	Buy	16,667 +10,221	+159%	+$3.01M	0.01%	628
2020 Q1	$1.31M	Sell	6,446 -67,721	-91%	-$21.6M	﹤0.01%	676
2019 Q4	$33.2M	Hold	74,167	–	–	0.08%	280
2019 Q3	$22.8M	Hold	74,167	–	–	0.06%	336
2019 Q2	$23.6M	Buy	74,167 +15,000	+25%	+$5.19M	0.06%	329
2019 Q1	$24.8M	Hold	59,167	–	–	0.06%	333
2018 Q4	$18M	Buy	59,167 +36,427	+160%	+$11.8M	0.05%	361
2018 Q3	$8.19M	Hold	22,740	–	–	0.02%	573
2018 Q2	$8.32M	Buy	+22,740	New	+$8.1M	0.02%	593

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Adage Capital Partners's EIGR Position: Q4 2022 in Review

Adage Capital Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 32,057 shares — an estimated $7.24M sold.

Adage Capital Partners first reported a position in EIGR in Q2 2018 and held it in 13 quarters. The position peaked at $33.2M in Q4 2019. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

Adage Capital Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Adage Capital Partners sold 32,057 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $7.24M.
Adage Capital Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2018 and held it in 13 quarters.
Adage Capital Partners's Eiger BioPharmaceuticals, Inc. position peaked at $33.2M in Q4 2019.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Adage Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.